ATLANTA -- (BUSINESS WIRE) -- Amniox Medical, Inc., a developer and marketer of restorative therapies processed from amniotic membrane and umbilical cord, announces that it was granted the American Podiatric Medical Association (APMA) Seal of Approval for its NEOX Wound Matrix and CLARIX Regenerative Matrix product lines.
As part of its mission, APMA strives to provide reliable information about the quality and effectiveness of available products and therapies to clinicians and patients. The APMA Seal of Approval is granted to products found to promote good foot health.
“The APMA Seal of Approval is awarded after a rigorous scientific review by a group of APMA member podiatrists. The committee examines information about the product’s safety, quality control, and other data,” said APMA Executive Director and CEO Glenn B. Gastwirth, DPM. “Amniox Medical’s NEOX and CLARIX have received the APMA Seal of Approval in recognition of their value and benefit as part of a wound care regimen overseen by a podiatric physician.”
Amniox Medical is the only provider of a human tissue matrix composed of both amniotic membrane and umbilical cord. These placental tissues have innate regenerative properties that can be preserved and transplanted to other environments. The Company’s amniotic membrane/umbilical cord matrix comprises key proteins, cytokines and growth factors that have been shown to modulate inflammation and promote regeneration of normal tissue. Amniox utilizes its proprietary CryoTek™ process, a cryopreservation technology, to preserve the natural biological and structural integrity of these tissues.
“We are very proud to have our entire product offering recognized by APMA,” said Aaron Smith, General Manager of Amniox Medical. “We know that APMA performs a rigorous review of any product under consideration for its Seal of Approval and are honored by their recognition of the safety, quality and extensive scientific evidence supporting our products.”
Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing restorative therapies processed from amniotic membrane and umbilical cord matrix utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products.
TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, more than 130,000 human implants have been conducted using the Company’s patented CryoTek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.
The American Podiatric Medical Association (APMA) is the nation's leading professional organization for today’s podiatrists. Doctors of Podiatric Medicine (DPMs) are qualified by their education, training, and experience to diagnose and treat conditions affecting the foot, ankle, and structures of the leg. APMA has 53 state component locations across the United States and its territories, with a membership of more than 12,000 podiatrists. All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit www.apma.org.